Where can I find news about TARS?

The latest press releases, SEC filings, and earnings call transcripts for Tarsus Pharmaceuticals, Inc. (TARS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.

Where are TARS's SEC filings?

Tarsus Pharmaceuticals, Inc. (TARS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

When was TARS's last earnings call?

The most recent earnings call transcript for Tarsus Pharmaceuticals, Inc. (TARS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

TARS

Tarsus Pharmaceuticals, Inc.

NASDAQ·Biotechnology · Healthcare

$58.37$1.11+1.94%

Market cap$2.51B·Jul 22 3:14 PM UTC

Press Releases

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor.
globenewswire.comJul 13, 2026 · 4:05 PM
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.
marketbeat.comJul 11, 2026 · 10:02 AM
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.
benzinga.comJul 9, 2026 · 1:01 PM
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
seekingalpha.comJul 9, 2026 · 2:12 AM
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
globenewswire.comJul 8, 2026 · 4:05 PM
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.comJul 8, 2026 · 1:01 PM
Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
zacks.comJul 3, 2026 · 6:06 AM
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:
globenewswire.comMay 28, 2026 · 4:30 PM

SEC Filings

8-K
Jul 13, 2026View on SEC
8-K
Jul 8, 2026View on SEC
8-K
Jun 29, 2026View on SEC
SC 13G
May 15, 2026View on SEC
SC 13G/A
May 15, 2026View on SEC
SC 13G/A
May 8, 2026View on SEC

Transcripts

PRO

Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.

Click below to see what's inside, then upgrade to read every transcript for TARS and 80,000+ other tickers.

Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.

Frequently Asked Questions About TARS

Where can I find news about TARS?: The latest press releases, SEC filings, and earnings call transcripts for Tarsus Pharmaceuticals, Inc. (TARS) are listed on this page. Press releases come from the company's investor relations feed; filings come directly from SEC EDGAR.
Where are TARS's SEC filings?: Tarsus Pharmaceuticals, Inc. (TARS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
When was TARS's last earnings call?: The most recent earnings call transcript for Tarsus Pharmaceuticals, Inc. (TARS) is on this page with the full speaker-by-speaker conversation. Older quarter transcripts are also available — click any past quarter pill to load it.

Tarsus Pharmaceuticals, Inc.

Frequently Asked Questions About TARS

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug